Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Otolaryngology Unit, San Giovanni-Addolorata Hospital, Rome, Italy.
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):2719-2725. doi: 10.1007/s00405-021-07140-6. Epub 2021 Oct 23.
Cribriform adenocarcinoma of the tongue and minor salivary glands (CATMSG) is a rare neoplasm, accounting for less than 1% of salivary gland tumors. In the past it has been considered a possible variant of polymorphous low-grade adenocarcinoma (PLGA), while nowadays it is accepted as a provisional entity in the WHO classification. The aim of this paper is to systematically review the existing literature about CATMSG with a particular attention to differential diagnosis and prognostic factors.
This study was performed in accordance with the PRISMA checklist. A comprehensive search in PubMed, Cochrane, and Google Scholar databases was carried out in June 2021, in partnership with a medical librarian, without time restriction. Search items include the following keywords: "cribriform adenocarcinoma of the tongue" OR "cribriform adenocarcinoma of the tongue and minor salivary glands."
A total of 56 patients were evaluated. Patient age across the studies ranged from 13 to 85 years (mean 59.6 year). The most common site of involvement was the tongue (58.9%), followed by palate (19.6%), tonsil (7.1%), buccal (3.6%) and reticular mucosa (3.6%), lip (3.6%), retromolar pad (1.7%), and floor of the mouth (1.7%). Lymph node involvement at the diagnosis was very common (58.9%), while there was no evidence of patients diagnosed with metastatic disease. The most common surgical approach was surgical excision (17, 30.3%); neck dissection was performed in 16 patients (28%). Radiotherapy was the most common adjuvant treatment reported (46.4%); only one patient underwent adjuvant chemotherapy (1.7%). Five patients experienced a recurrence (8.8%).
To our knowledge, only 56 five cases of CATMSG have been previously described. The results of this review seem to confirm the low frequency of relapses and distant metastases, but we observed that almost 60% of cases presented with cervical lymph node involvement. In our opinion, CATMSG should be considered as a distinct tumor entity from PLGA.
舌和小唾液腺筛状腺癌（CATMSG）是一种罕见的肿瘤，占唾液腺肿瘤的比例不到 1%。过去，它被认为是多形性低度恶性腺癌（PLGA）的一种可能变体，而现在它被WHO 分类接受为一种暂定实体。本文旨在通过特别关注鉴别诊断和预后因素，对 CATMSG 的现有文献进行系统回顾。
本研究按照 PRISMA 清单进行。2021 年 6 月，与一名医学图书馆员合作，在 PubMed、Cochrane 和 Google Scholar 数据库中进行了全面搜索，没有时间限制。搜索项包括以下关键字：“舌筛状腺癌”或“舌和小唾液腺筛状腺癌”。
共评估了 56 例患者。研究中患者的年龄从 13 岁到 85 岁（平均 59.6 岁）不等。最常见的受累部位是舌（58.9%），其次是腭（19.6%）、扁桃体（7.1%）、颊（3.6%）和网状黏膜（3.6%）、唇（3.6%）、磨牙后垫（1.7%）和口底（1.7%）。诊断时淋巴结受累非常常见（58.9%），但没有证据表明患者患有转移性疾病。最常见的手术方法是手术切除（17，30.3%）；16 例患者行颈清扫术（28%）。放射治疗是最常见的辅助治疗方法（46.4%）；仅 1 例患者接受辅助化疗（1.7%）。5 例患者复发（8.8%）。
据我们所知，之前仅描述了 56 例 CATMSG。本综述的结果似乎证实了复发和远处转移的低频率，但我们观察到近 60%的病例存在颈部淋巴结受累。在我们看来，CATMSG 应被视为与 PLGA 不同的肿瘤实体。
